Because neuroimmune interactions are important in the development of neuropathy and considering the promising results obtained in our biochemical studies, we suggest that the pharmacological blockade of CCR4 may represent a new strategy for neuropathic pain polytherapy in the future. This evidence concerns the gene CCR4 and neuropathy.